Biocon is currently trading at Rs. 412.25, up by 19.60 points or 4.99% from its previous closing of Rs. 392.65 on the BSE.
The scrip opened at Rs. 394.00 and has touched a high and low of Rs. 414.00 and Rs. 394.00 respectively. So far 1, 61,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 414.00 on 18-Dec-2013 and a 52 week low of Rs. 255.00 on 04-Mar-2013.
Last one week high and low of the scrip stood at Rs. 405.15 and Rs. 378.85 respectively. The current market cap of the company is Rs. 8,238 crore.
The promoters holding in the company stood at 60.97% while Institutions and Non-Institutions held 18.06% and 20.97% respectively.
Biocon, Asiais premier biotechnology company, and Quark Pharmaceuticals, Inc, a world leader in the discovery and development of siRNA -based therapeutics, have entered into a Licensing & Collaboration agreement for the development of a range of siRNA (small interfering RNA) based novel therapeutics.
This collaboration will enable Biocon to co-develop, manufacture & commercialize QPI-1007, a novel siRNA drug candidate for ophthalmic conditions, for India and other key markets. Biocon will have access to Quark's innovative and proprietary siRNA technology platform that can be leveraged for the development of novel therapeutics for various unmet medical needs.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: